SBC Medical Group (NASDAQ:SBC) Upgraded to “Strong-Buy” at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of SBC Medical Group (NASDAQ:SBC – Free Report) from a buy rating to a strong-buy rating in a report published on Saturday morning,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on SBC. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of SBC Medical Group in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SBC Medical Group in a research report on Wednesday, August 19th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.50.

Read Our Latest Research Report on SBC Medical Group

SBC Medical Group Stock Performance

Shares of SBC stock opened at $4.75 on Friday. The stock has a fifty day moving average price of $3.66 and a 200 day moving average price of $3.53. The stock has a market cap of $488.54 million, a PE ratio of 10.11 and a beta of 0.63. SBC Medical Group has a 1 year low of $2.78 and a 1 year high of $4.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31.

SBC Medical Group (NASDAQ:SBC – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). SBC Medical Group had a net margin of 27.99% and a return on equity of 18.47%. The firm had revenue of $49.19 million during the quarter, compared to analysts’ expectations of $45.37 million. Sell-side analysts forecast that SBC Medical Group will post 0.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SBC. BlackRock Inc. acquired a new position in shares of SBC Medical Group in the second quarter valued at approximately $2,846,000. Citadel Advisors LLC acquired a new stake in SBC Medical Group during the second quarter worth approximately $446,000. Segall Bryant & Hamill LLC acquired a new stake in SBC Medical Group during the first quarter worth approximately $340,000. Bank of New York Mellon Corp purchased a new stake in SBC Medical Group in the 2nd quarter worth approximately $83,000. Finally, Central Pacific Bank Trust Division purchased a new stake in SBC Medical Group in the 2nd quarter worth approximately $74,000. 60.82% of the stock is currently owned by hedge funds and other institutional investors.

SBC Medical Group Company Profile

(Get Free Report)

SBC Medical Group (NASDAQ: SBC) is a Japan-based medical services and management company focused primarily on the aesthetic medicine sector. Through its affiliated medical corporations and clinic network, the company supports the operation of facilities offering cosmetic surgery, cosmetic dermatology and related elective treatments.

The company provides a range of management and operational services to affiliated clinics, including branding and marketing, staff recruitment and training, purchasing, information technology, administrative support and business consulting.

Read More